The Medicines Company (NASDAQ:MDCO) Ratings Summary as of May 17, 2018

May 17, 2018 - By Ira Colvard

The Medicines Company (NASDAQ:MDCO) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.25. That’s change of 0.47, from 2017Q3’s 0.78. 26 investors sold all, 51 reduced holdings as The Medicines Company ratio improved. 68 rose positions while 28 funds amassed positions. Funds hold 89.44 million shares thus 5.03% more from 2017Q3’s 85.15 million shares.
Focused Wealth Mngmt holds 0.01% or 700 shs in its capital. Teachers Retirement System Of The State Of Kentucky has 46,090 shs for 0.01% of their capital. Greenlight Capital holds 0.5% or 1.00M shs in its capital. Slate Path Capital Lp stated it has 1.73M shs. 357 are held by Glenmede Trust Na. State Street has invested 0% in The Medicines Company (NASDAQ:MDCO). Putnam Lc owns 2.08M shs or 0.13% of their US capital. Three Bays Capital L P holds 2.56M shs or 3.93% of its capital. Qs Invsts Limited Liability Company stated it has 0% in The Medicines Company (NASDAQ:MDCO). Piedmont Invest Limited Liability Corp owns 44,634 shs. Whittier Commerce Of Nevada owns 1,359 shs for 0% of their capital. Iguana Healthcare Management Ltd Liability Corp invested in 1.07% or 60,000 shs. Millennium Management Lc reported 256,352 shs. Pacad Invest has invested 0.04% of its capital in The Medicines Company (NASDAQ:MDCO). Endurant Cap Mgmt Ltd Partnership invested 0.34% of its capital in The Medicines Company (NASDAQ:MDCO).

The Medicines Company registered $783,400 net activity with 1 insider purchase and 3 insider sales since December 7, 2017. On Thursday, December 7 Shares for $5.31 million were bought by ESHELMAN FREDRIC N. Shares for $574,200 were sold by KESSLER ARMIN M on Tuesday, January 16. MEANWELL CLIVE sold $3.71M worth of The Medicines Company (NASDAQ:MDCO) or 136,250 shs on Friday, December 15.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

In total 3 analysts cover Medicines Co (NASDAQ:MDCO). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:MDCO)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. In Monday, January 15 report Oppenheimer maintained it with “Buy” rating and $50.0 target. The company rating was upgraded by Citigroup on Monday, January 22. On Thursday, February 22 the stock of The Medicines Company (NASDAQ:MDCO) has “Hold” rating given by Oppenheimer. On Wednesday, November 29 Oppenheimer upgraded The Medicines Company (NASDAQ:MDCO) rating. Oppenheimer has “Buy” rating and $50.0 target. On Thursday, March 22 the company was maintained by Oppenheimer. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain
29/11/2017 Broker: Oppenheimer Rating: Buy New Target: $50.0 Upgrade

The stock increased 0.22% or $0.07 during the last trading session, reaching $32.2.The Medicines Company has volume of 288,319 shares. Since May 17, 2017 MDCO has declined 34.73% and is downtrending. MDCO underperformed by 46.28% the S&P500.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is worth $2.37 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Last it reported negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news released recently go to: Fool.com, Streetinsider.com, Streetinsider.com, Fool.com or Seekingalpha.com. The titles are as follows: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” released on May 17, 2018, “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” on May 15, 2018, “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” with a publish date: May 07, 2018, “Alnylam Looks Forward” and the last “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” with publication date: April 25, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.